Garrett Winslow Biography and Net Worth

General Counsel of Damora Therapeutics, Inc. Common Stock

Presently, Garrett M. Winslow holds the position of Senior Vice President & General Counsel of Galecto, Inc.

In his past career he was Principal at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC and Secretary, Vice President-Legal & General Counsel at Spring Bank Pharmaceuticals, Inc.

Garrett M. Winslow received a graduate degree from Boston University School of Law, a graduate degree from Suffolk University Law School and an undergraduate degree from the University of Washington.

What is Garrett Winslow's net worth?: The estimated net worth of Garrett Winslow is at least $70.46 thousand as of July 6th, 2026. Mr. Winslow owns 2,289 shares of Damora Therapeutics, Inc. Common Stock stock worth more than $70,455 as of July 9th. This net worth evaluation does not reflect any other investments that Mr. Winslow may own. Learn More about Garrett Winslow's net worth.
How do I contact Garrett Winslow?: The corporate mailing address for Mr. Winslow and other Damora Therapeutics, Inc. Common Stock executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Damora Therapeutics, Inc. Common Stock can also be reached via phone at 45-7070-5210 and via email at [email protected]. Learn More on Garrett Winslow's contact information.
Has Garrett Winslow been buying or selling shares of Damora Therapeutics, Inc. Common Stock?: During the past quarter, Garrett Winslow has sold $7,345.10 of Damora Therapeutics, Inc. Common Stock stock. Most recently, Garrett Winslow sold 245 shares of the business's stock in a transaction on Monday, July 6th. The shares were sold at an average price of $29.98, for a transaction totalling $7,345.10. Following the completion of the sale, the general counsel now directly owns 2,289 shares of the company's stock, valued at $68,624.22. Learn More on Garrett Winslow's trading history.
Who are Damora Therapeutics, Inc. Common Stock's active insiders?: Damora Therapeutics, Inc. Common Stock's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Damora Therapeutics, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Damora Therapeutics, Inc. Common Stock?: In the last year, insiders at the sold shares 3 times. They sold a total of 1,080 shares worth more than $25,201.45. The most recent insider tranaction occured on July, 6th when General Counsel Garrett Winslow sold 245 shares worth more than $7,345.10. Insiders at Damora Therapeutics, Inc. Common Stock own 0.4% of the company. Learn More about insider trades at Damora Therapeutics, Inc. Common Stock.
Information on this page was last updated on 7/6/2026.

Garrett Winslow Insider Trading History at Damora Therapeutics, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/6/2026	Sell	245	$29.98	$7,345.10	2,289
12/3/2021	Buy	80	$62.00	$4,960.00

Garrett Winslow Buying and Selling Activity at Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $30.78

$27.29

$31.35

50 Day Range

MA: $24.24

$20.07

$30.78

2 Week Range

Now: $30.78

$2.45

$38.33

Volume

845,659 shs

Average Volume

913,842 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46